Sign inJoin waitlistJoin the waitlist

CH

Christopher Hourigan

Medical Oncology

Credentials: · · ·

History

Hematology and Medical Oncology
2010–2013
Internal Medicine
2007–2010
Doctor of Medicine
2002–2006

Research

Functional genomic landscape of acute myeloid leukaemia
Nature · 2018 · 1,111 citations
Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease
New England Journal of Medicine · 2020 · 986 citations
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
Review · Blood · 2018 · 856 citations

Mark Litzow
19 papers
Wael Saber
18 papers
Partow Kebriaei
17 papers
Marcos de Lima
15 papers
Gail Roboz
14 papers
Roland Walter
14 papers
Amer Zeidan
13 papers
MB
Minocher Battiwalla
13 papers
Uma Borate
13 papers
AB
Austin Barrett
12 papers
Catherine Lai
12 papers
SD
Steven Devine
12 papers

Grants

Development of a Universal Assay for Minimal Residual Disease in Acute Myeloid Leukemia Using Duplex Sequencing
National Cancer Institute · R44
PI · $1.1M · Twinstrand Biosciences, Inc.
2018–2027
Detection, Prevention and Treatment of Acute Myeloid Leukemia (AML) Relapse.
National Heart, Lung, and Blood Institute · ZIA
Contact PI · $21M · National Heart, Lung, and Blood Institute

Clinical trials

Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia
Principal investigator · Completed · Phase 1, Phase 2
National Heart, Lung, and Blood Institute (NHLBI)
2016–2019
Biomarkers for Personalized Early Assessment of Response During Salvage Chemotherapy in People With Relapsed or Refractory Acute Myeloid Leukemia (PEARL15)
Principal investigator · Completed
National Heart, Lung, and Blood Institute (NHLBI)
2015–2018